Table 5.

Subgroup associations of dysnatremia with AKI development

	AKI (hyponatremia sample)		AKI (hypernatremia sample)
	HR (95% CI)	p for interaction	HR (95% CI)	p for interaction
Age ≥ 60	4.32 (3.26, 5.71)	< 0.001	4.26 (2.80, 6.48)	0.003
Age < 60	1.53 (1.34, 1.76)		2.14 (1.81, 2.52)
Male	2.58 (2.12, 3.14)	< 0.001	3.23 (2.53, 4.13)	0.075
Female	1.65 (1.41, 1.92)		2.43 (2.00, 2.95)
Cardiovascular	3.35 (2.73, 4.10)	< 0.001	4.39 (3.36, 5.73)	< 0.001
No cardiovascular	1.42 (1.22, 1.66)		1.85 (1.53, 2.23)
Malignancies	1.85 (1.60, 2.15)	0.069	2.73 (2.30, 3.26)	0.652
No malignancies	2.36 (1.91, 2.92)		2.52 (1.84, 3.45)
Gastrointestinal	1.85 (1.61, 2.11)	0.005	2.68 (2.28, 3.15)	0.960
No gastrointestinal	2.93 (2.19, 3.91)		2.71 (1.97, 4.40)
Genito/urinary	2.04 (1.78, 2.34)	0.031	2.75 (2.32, 3.27)	0.089
No genito/urinary	1.47 (1.13, 1.92)		2.00 (1.44, 2.77)
Endocrine/metabolic	2.25 (1.96, 2.59)	< 0.001	3.10 (2.61, 3.70)	0.001
No endocrine/metabolic	1.34 (1.05, 1.71)		1.71 (1.25, 2.34)
Infectious	2.08 (1.83, 2.37)	0.085	2.59 (2.20, 3.05)	0.314
No infectious	1.46 (1.00, 2.14)		3.29 (2.12, 5.11)
Respiratory	2.21 (1.93, 2.54)	< 0.001	2.71 (2.24, 3.28)	0.100
No respiratory	1.23 (0.96, 1.59)		2.06 (1.58, 2.69)
eGFR ≥ 60	1.37 (1.17, 1.61)	< 0.001	1.95 (1.61, 2.36)	0.123
eGFR < 60	2.28 (1.89, 2.73)		2.51 (1.94, 3.24)